Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Onvansertib gets FDA fast track for RAS-mutated colorectal cancer. The FDA has granted fast track designation to onvansertib combined with FOLFIRI and bevacizumab for first-line treatment of KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC). Phase 2 data showed a 72.2% response rate with the combo vs. 42.1% with standard chemotherapy alone — a meaningful step forward for a patient population with no specifically approved frontline options.
Onvansertib gets FDA fast track for hard-to-treat colorectal cancer
The FDA has granted fast track designation to onvansertib — a PLK1 inhibitor — combined with FOLFIRI and bevacizumab as a frontline treatment for adults with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC). This designation was driven by promising data from the ongoing randomized phase 2 CRDF-004 trial, which enrolled 110 treatment-naïve patients with RAS-mutated mCRC.
In the intent-to-treat population, the onvansertib combination delivered a confirmed objective response rate (ORR) of 72.2%, compared to 42.1% with standard FOLFIRI plus bevacizumab. As of the September 2026 data cutoff, median progression-free survival had not yet been reached in the combination arm, while pooled standard-of-care arms clocked in at roughly 11 months — and every patient still on the combo had been treated for 21+ months.
By the Numbers
Why it matters: RAS mutations are among the most common — and most treatment-resistant — in colorectal cancer, and no frontline therapy is specifically approved for this group. If phase 3 data hold up, onvansertib could fill a major gap in care for these patients.